Galderma Pioneers NDA Path Into OTC Acne Treatment Market
This article was originally published in The Rose Sheet
Executive Summary
FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical acne treatment for consumers 12 years old and up.
You may also be interested in...
Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions
From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.
Private-Equity Investors Poised To Acquire Nestlé Skin Health, Promising US Expansion
After working hard to turnaround its troubled Skin Health dermatology operation, Nestlé looks set to offload the business to a consortium of private-equity buyers. The consortium - led by EQT - have identified expansion in the US consumer health market as an immediate priority.
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.